Chimeric antigen receptor (CAR)-T cell therapy is one of the most promising advances in
cancer treatment. It is based on genetically modified T cells to express a CAR, which …

Autoimmune disease, caused by unwanted immune responses to self-antigens, affects
millions of people each year and poses a great social and economic burden to individuals …

Immunological protection of transplanted stem cell-derived islet (SC-islet) cells is yet to be
achieved without chronic immunosuppression or encapsulation. Existing genetic …

Regulatory T (Treg) cells ensure tolerance against self-antigens, limit excessive
inflammation, and support tissue repair processes. Therefore, Treg cells are currently …

T cells modified for expression of Chimeric Antigen Receptors (CARs) were the first gene-
modified cell products approved for use in cancer immunotherapy. CAR-T cells engineered …

A primary goal in transplantation medicine is the induction of a tolerogenic environment for
prevention of transplant rejection without the need for long-term pharmacological …

Since their discovery, CD4+ CD25hiFOXP3hi regulatory T cells (Tregs) have been firmly
established as a critical cell type for regulating immune homeostasis through a plethora of …

Alloantigen-specific regulatory T cell (Treg) therapy is a promising approach for suppressing
alloimmune responses and minimizing immunosuppression after solid organ …

Regulatory T cells (Tregs) have enormous therapeutic potential to treat a variety of
immunopathologies characterized by aberrant immune activation. Adoptive transfer of ex …

CAR (Chimeric Antigen Receptor) T-cell therapy has revolutionized the field of oncology in
recent years. This innovative shift in cancer treatment also provides the opportunity to …